Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • Chapter 14 - Tight glucose control using intensive insulin therapy in the critically ill

  • from Section 3 - Endocrine disorders in the critically ill
  • Edited by George M. Hall, St George's Hospital, London, Jennifer M. Hunter, University of Liverpool, Mark S. Cooper, University of Birmingham
  • Book:
    Core Topics in Endocrinology in Anaesthesia and Critical Care
    Published online:
    06 July 2010
    Print publication:
    01 April 2010, pp 134-143

  • Summary

    Multiple endocrine neoplasia (MEN) is a rare autosomal dominant disorder characterised by primary tumours in at least two different endocrine glands. In the early twentieth century, a syndrome that involved the concurrence of tumours of the parathyroid glands, the pancreatic islets and the anterior pituitary gland was described. The gene that codes for menin is located on chromosome 11q12-13 and transcribes an mRNA consisting of 10 exons which encodes the 610 amino acid protein, menin. MEN 2 is a rare disorder with a prevalence of one in 20,000, and like MEN 1, is an dominant syndrome. The RET protooncogene, located on chromosome 10q11.2, transcribes an mRNA consisting of 21 exons. Molecular information has revolutionised the understanding and treatment of MEN 2. The increasing knowledge of the molecular mechanisms of MEN coupled with the clinical outcome and the availability of genetic testing has greatly reduced its morbidity and mortality.